Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Notes Payables (2016)

United Therapeutics' Notes Payables history spans 8 years, with the latest figure at $900000.0 for Q2 2016.

  • For Q2 2016, Notes Payables fell 97.21% year-over-year to $900000.0; the TTM value through Jun 2016 reached $900000.0, down 97.21%, while the annual FY2015 figure was $5.4 million, 95.73% down from the prior year.
  • Notes Payables for Q2 2016 was $900000.0 at United Therapeutics, down from $5.4 million in the prior quarter.
  • Across five years, Notes Payables topped out at $224.7 million in Q3 2014 and bottomed at $900000.0 in Q2 2016.
  • The 5-year median for Notes Payables is $90.9 million (2013), against an average of $99.4 million.
  • The largest annual shift saw Notes Payables surged 5059.88% in 2013 before it tumbled 97.21% in 2016.
  • A 5-year view of Notes Payables shows it stood at $1.3 million in 2012, then soared by 5059.88% to $66.6 million in 2013, then soared by 89.77% to $126.4 million in 2014, then tumbled by 95.73% to $5.4 million in 2015, then plummeted by 83.33% to $900000.0 in 2016.
  • Per Business Quant, the three most recent readings for UTHR's Notes Payables are $900000.0 (Q2 2016), $5.4 million (Q1 2016), and $5.4 million (Q4 2015).